Piotr Tutka

Piotr Tutka

Auto-generated profile, based on publicly available information

Piotr Tutka

Department of Experimental and Clinical Pharmacology, University of Rzeszów, Kopisto 2a, 35-959 Rzeszów, Poland

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


27 November 2006 in Tobacco Control
Verified
Journal Article
Closed access
PDF file
WZWitold Zatonski
Witold Zatonski
MCMagdalena Cedzynska
Magdalena Cedzynska
PTPiotr Tutka
Piotr Tutka
RWRobert West
Robert West
Objectives:Cytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking cessation for 40 years. Cytisine is a partial agonist with high affinity binding to the α4β2 nicotinic acetylcholine receptor believed to be central to the rewarding effect of nicotine. There is insufficient information on effectiveness to warrant licensing by modern standards. To assess whether full-scale controlled trials are warranted, this study sought to obtain an estimate of the 12-month continuous abstinence rates of smokers using cytisine with minimal behavioural support.Design:An uncontrolled, open-label trial.Setting:A smokers’ clinic in an oncology centre in Warsaw, Poland.Subjects:436 consecutive attendees of the smokers’ clinic of whom 191 were male. The mean dependence score (Fagerstrom Test for Nicotine Dependence) was 6.1.Intervention:The standard regimen of Tabex (cytisine) was used, involving 25 days of treatment with minimal behavioural support.Main outcome measure:Self-reported continuous abstinence for 12 months; with abstinence verified by carbon monoxide at the final follow up (after 12 months).Results:60 participants (13.8% of the total sample) were abstinent for 12 months. Of the 315 subjects, who had taken the drug, 49 (15.5%) stopped cytisine because of adverse effects (mostly gastric disturbances and nausea), although they were not serious. The frequency of the minor adverse effects, primarily gastric disturbance, was similar to that observed in previous studies with the drug.Conclusions:The long-term abstinence rates were similar to those observed in smokers receiving nicotine replacement therapy. Full-scale randomised trials of cytisine (Tabex), conducted to the standards required by regulatory authorities, are warranted.

1 November 1996 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
MGMarco Gariboldi
Marco Gariboldi
PTPiotr Tutka
Piotr Tutka
RSRosario Samanin
Rosario Samanin
AVAnnamaria Vezzani
Annamaria Vezzani
1 We studied whether the stimulation of 5-HT1A receptors by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), a specific 5-HT1A receptor agonist, reduced electroencephalographic (EEG) seizures induced by intrahippocampal injection of 0.04 μg in 0.5 μl of the glutamate analogue kainic acid in freely-moving rats. 2 Pretreatment with 8-OH-DPAT 15 min earlier at the same site as kainic acid injection, caused a dose-dependent decrease of kainic acid-induced seizure activity. One and 10 μg significantly reduced the total time spent in seizures by 72% on average and the total number of seizures by 58% (P < 0.01) and 43% (P < 0.05) respectively. The latency to onset of the first seizure was increased 2.8 times (P < 0.01) only after 1 μg 8-OH-DPAT; 0.1 μg was ineffective on all seizure parameters. 3 Systemic administration of 25,100 and 1000 μg kg−1 8-OH-DPAT significantly reduced the total number of seizures and the total time in seizures induced by intrahippocampal kainic acid by 52% and 74% on average. The latency to onset of the first seizure was delayed 1.8 times by 100 and 1000 μg kg−1 (P < 0.05). 4 The anticonvulsant action of 8-OH-DPAT given intrahippocampally or systemically was significantly blocked by 5 μg, but not 1 μg WAY 100635, a selective 5-HT1A receptor antagonist, administered in the hippocampus before the agonist. 5 These results indicate that postsynaptic 5-HT1A receptors in the hippocampus mediate the anticonvulsant action of 8-OH-DPAT and that their stimulation has an inhibitory role in the generation of limbic seizures.


1 July 1996 in NeuroReport
Verified
Journal Article
Closed access
PTPiotr Tutka
Piotr Tutka
PKPawel Klonowski
Pawel Klonowski
JDJacek Dzieciuch
Jacek Dzieciuch
ZKZdzislaw Kleinrok
Zdzislaw Kleinrok
SCStanislaw J. Czuczwar
Stanislaw J. Czuczwar
The effects of nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (NNA) on seizures induced by excitatory amino acids, bicuculline, pentylenetetrazol and pilocarpine were studied in mice. NNA (10 and 40 mg kg-1, i.p.) enhanced the susceptibility to intracerebroventricular (i.c.v.) kainate (KA) which was reflected by a decrease in its convulsant dose 50% (CD50) from 0.66 nmol to 0.38 and 0.29 nmol/mouse, respectively. Also, NNA (40 mg kg-1) increased the KA-induced mortality. Conversely, NNA (40 mg kg-1) produced an anticonvulsant effect against i.c.v. glutamate whose CD50 value was significantly elevated from 0.49 mumol to 0.84 mumol/mouse. The convulsive activity of i.c.v. N-methyl-D-aspartic acid (NDMA), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and trans-(+/-)-1-amino-1,3-cyclopentanedicarboxylic acid (trans-ACPD) was not affected by the pretreatment with NNA (40 mg kg-1). NNA (5-40 mg kg-1) also potentiated the convulsive action of systematic KA and KA-induced mortality but (up to 40 mg kg-1) remained without effect on seizures produced by bicuculline, N-methyl-D, L-aspartic acid (NMDLA), pentylenetetrazol, and pilocarpine. Only bicuculline-produced lethality was significantly enhanced. It may be concluded that the manipulation of the NO level affects differently seizures arising from a diffuse stimulation of glutamate receptors and seizures resulting from an activation of an individual subtype of these receptors. It is noteworthy that in the majority of convulsive tests used in this study, NNA exerted no modulatory effect.